Hologic — Q2 2025 Earnings Presentation
48 slides from Hologic's earnings presentation, May 1, 2025
Slide 1: Champions of Women's Health Q2'25 Corporate Presentation
Champions of Women’s Health Q2’25 Corporate Presentation
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or other
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company has presented the following non-GAAP financial measures in this presentation: constant currency revenues; organic revenues; organic revenues excluding COVID-19; non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective t
Slide 4: Presentation Outline
Presentation Outline Overview Track record of dependable growth Market-leading core franchises Competencies for future success Strong financials 4
Slide 5: Investment Thesis
Investment Thesis 1. Solid revenue/EPS growth 2. Market leading brands 3. Multiple growth platforms 4. Early-stage growth opportunities 5. Strong operating margins 6. Exceptional free cash flow 7. Fortress balance sheet 5
Slide 6: Hologic Overview
Hologic Overview Champions of women’s health, operating across three segments By Division By Type By Geography Surgical Service 16% and Other INTL 19% 25% Diagnostics 44% Capital Consumables 19% 62% Breast and Skeletal US 40% 75% 6 Note: Based on FY24 revenue.
Slide 7: Presentation Outline
Presentation Outline Overview Track record of dependable growth Market-leading core franchises Competencies for future success Strong financials 7
Slide 8: Mid-Single-Digit Total Sales Growth
Mid-Single-Digit Total Sales Growth $4,030 $641 $2,511 $308 $1,782 $1,167 $1,607 $1,036 2014 2024 Breast & Skeletal Health Diagnostics Surgical 8 Note: Dollars in millions, as reported. 2014 excludes Roka royalty payment of $20.1M. Revenue from divested Blood Screening business is included in both p
Slide 9: Double-Digit Non-GAAP EPS Growth
Double-Digit Non-GAAP EPS Growth $4.08 $1.46 2014 2024 9 Note: Non-GAAP EPS for 2014 excludes ~$0.05 one-time contribution from amending Roka license.
Slide 10: Presentation Outline
Presentation Outline Overview Track record of dependable growth Market-leading core franchises Competencies for future success Strong financials 10
Slide 11: Diagnostics
Diagnostics Powered by molecular growth $1,752 $79 $943 $1,194 $459 $485 $479 2014 2024 Cytology & Perinatal MDx (ex. Covid Assays) Covid Assays 11 Note: Dollars in millions. Excludes Roka royalty payment of $20.1M in 2014 and revenue from the divested Blood Screening business of $223.3M in 2014 and
Slide 12: Panther Placements
Panther Placements Expanded global footprint providing foundation for future growth >3,300 ~1,600 >1,700 ~800 ~1,700 ~500 ~200 ~1,000 ~300 2014 2019 2024 US International 12 Note: numbers are rounded.
Slide 13: Panther Assays
Panther Assays Broadening menu from core STIs into multiple testing categories 23 16 4 2014 2019 2024 13 Note: Figures represent number of FDA cleared assays available in the US.
Slide 14: Breast & Skeletal Health
Breast & Skeletal Health More recurring revenue $1,604 $84 $208 $1,036 $337 $91 $150 $165 $609 $357 $274 $366 2014 2024 Gantry Service Interventional Accessories and Equipment Skeletal 14 Note: Dollars in millions. Excludes $2.6M of revenue from the divested SSI business in 2024. Interventional incl
Slide 15: Breast Health 3D Gantries
Breast Health 3D Gantries Establishing 3D Mammography as the standard of care ~15,000 >4,000 >10,000 ~2,200 ~700 ~1,500 2014 2024 US International 15 Note: numbers are rounded.
Slide 16: Surgical
Surgical Doubled in size with an expanding portfolio $641 <$50 >$400 $308 <$100 >$200 <$200 2014 2024 NovaSure Tissue Removal Laparoscopy 16 Note: Dollars in millions.
Slide 17: Presentation Outline
Presentation Outline Overview Track record of dependable growth Market-leading core franchises Competencies for future success Strong financials 17
Slide 18: Unique Culture
Unique Culture • Purpose driven, results driven • Passion for women’s health • Highly engaged workforce of 7,000 • 98th percentile engagement compared to similar companies • 99th percentile for “Mission or purpose of my company makes me feel my job is important.” • Workplace recognition from Gallup,
Slide 19: Women's Health Champions
Women’s Health Champions • Hologic Global Women’s Health Index • Hologic Global Access Initiative • Project Health Equity • WTA partnership 19
Slide 20: Creating and Expanding Markets
Creating and Expanding Markets • Pap smear to ThinPrep Pap test • 2D to 3D mammography • MyoSure to treat uterine fibroids • High-throughput vaginitis testing • Plus many others… 20
Slide 21: Expanding Internationally
Expanding Internationally • Indirect to direct sales • Market access capabilities • Still in early innings $999 $533 2014 2024 21 Note: Dollars in millions. Organic revenue shown -- excludes Blood Screening in 2014 and SSI and Endomagnetics in 2024.
Slide 22: Adding New Growth Drivers
Adding New Growth Drivers • Organic innovation ▪ BV CV/TV assay M&A Intl ▪ Fluent fluid management Opportunity ▪ Genius digital cytology Organic Innovation • Tuck-in M&A New Growth Drivers ▪ Biotheranostics International Opportunity ▪ Endomagnetics Strong Foundation Market Leading Brands ▪ Gynesonic
Slide 23: Presentation Outline
Presentation Outline Overview Track record of dependable growth Market-leading core franchises Competencies for future success Strong financials 23
Slide 24: Profitability
Profitability Best-in-class operating margin Adjusted Operating Margin %* 30.0% 20.1% SPSIHE Average HOLX 24 *Adjusted operating margin % reflects non-GAAP operating margin divided by revenue, based on most recent fiscal year, as reported by FactSet (definitions may vary). HOLX is for full-year 2024
Slide 25: Strong Cash Flow
Strong Cash Flow Trailing 5-Yr Avg FCF Conversion %* Adjusted Free Cash Flow* 96% $1,048 80% $540 SPSIHE Average HOLX 2019 2024 Note: Dollars in millions. Free cash flow defined as cash flow from operations plus proceeds from the Department of Defense less capital expenditures and increase in equipm
Slide 26: Balance Sheet
Balance Sheet • Fortress balance sheet provides strategic flexibility Net Debt and Leverage Ratio* $3.5 • $5.7B deployed since FY20 • $3.6B on share repurchases 4.0x • $2.1B on M&A 2.3x 0.6x $1.1 • $1.6B of cash & investments as of Q2’25 0.8x • Ample firepower to fuel future growth 2014 Q2'25 26 Not
Slide 27: Revenue by Segment Q2'25
Revenue by Segment Q2’25 Delivered revenue at the high end of our guidance range in Q2’25 Q2’25 Revenue Q2’24 Revenue Change (CC) Diagnostics $453.6 $450.1 1.5% Organic Dx ex. COVID $407.4 $390.0 5.2% Organic Molecular Dx ex. COVID $288.9 $269.5 7.8% Breast Health $356.2 $384.6 (6.9%) Organic Breast
Slide 28: Financial Overview Q2'25 (GAAP)
Financial Overview Q2’25 GAAP Results $M, except EPS Q2’25 vs. Q2’24 Revenue $1,005.3 (1.2%) Gross Margin 37.5% (1,580) bps Operating Expenses $384.3 15.8% Operating Margin (0.7%) (2,140) bps Net Margin (1.7%) (1,840) bps Diluted EPS ($0.08) (111.1%) 28
Slide 29: Financial Overview Q2'25 (Non-GAAP)
Financial Overview Q2’25 Non-GAAP Results $M, except EPS Q2’25 vs. Q2’24 Revenue $1,005.3 (1.2%) and (0.5%) CC Organic $980.0 (3.0%) and (2.3%) CC Organic ex COVID $942.9 (1.4%) and (0.7%) CC Gross Margin 61.1% 40 bps Operating Expenses $312.9 1.7% Operating Margin 30.0% (40) bps Net Margin 23.2%
Slide 30: Financial Guidance
Financial Guidance 2025 Full Year* Q3’25* Reported % Increase Reported % Increase Guidance Guidance (Decrease) (Decrease) Revenue $4,050 – $4,100 0.5% to 1.7% $1,000 – $1,010 (1.1%) to (0.1%) GAAP Diluted EPS $2.47 – $2.57 (25.6%) to (22.6%) $0.85 – $0.88 3.7% to 7.3% Non-GAAP Diluted EPS $4.15 – $4
Slide 31: Financial Goal
Financial Goal Continue double-digit non-GAAP EPS growth, driven by: • Mid-single-digit revenue growth • Modest operating margin expansion • Regular acquisitions • Meaningful buybacks 31
Slide 32: For More Information
For More Information: Mike Watts Pete Sattler Corporate VP, Investor Relations Sr Manager, Investor Relations [email protected] [email protected]
Slide 33: Appendix
HEALTH Appendix HOLOGIC' |
Slide 34: Board of Directors
Board of Directors Steve MacMillan Amy M. Wendell Charles J. Dockendorff Nanaz Mohtashami Ludwig N. Hantson Chairman, President and Chief Executive Officer Lead Independent Director Former CFO and EVP, Covidien plc Managing Director at Russell Reynolds Associates Former CEO, Alexion Pharmaceuticals,
Slide 35: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) Reconciliation of Revenue Schedule Presented on Page 8 2024 2014 CAGR Consolidated Worldwide GAAP Revenue 4,030.3 2,530.7 Less: ROKA royalty payment - (20.1) Adjusted Revenue less Roka 4,030.3 2,510.6 4.8% 2024 2014 Consolidated Worldwide GAAP Revenue 4
Slide 36: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) Reconciliation of Revenue Schedule Presented on Page 11 2024 2014 CAGR Consolidated GAAP Diagnostics Revenue 1,782.0 1,186.8 Less: Blood Screening (30.3) (223.3) Less: ROKA royalty payment - (20.1) Adjusted Diagnostics Revenue less Roka and Blood Screen
Slide 37: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) Reconciliation of Operating Margin Schedule Presented on Page 24 2024 GAAP Income from Operations Margin Percentage 21.9% Impact of adjustments detailed in Fiscal 2024 Q4 earnings release 8.1% Non-GAAP Operating Margin Percentage 30.0% Reconciliation of
Slide 38: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) Reconciliation of Organic Revenue Presented on Pages 27 & 29 Three Months Ended March 29, 2025 March 30, 2024 Consolidated GAAP Revenue 1,005.3 1,017.8 Less: Blood Screening revenue (9.1) (6.9) Less: SSI revenue (0.2) (1.1) Less: Endomagnetics (9.7) - L
Slide 39: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) Reconciliation of Non-GAAP Income Statement Presented on Page 29 Three Months Ended March 29, 2025 March 30, 2024 Gross Profit: GAAP gross profit 377.3 542.3 Adjustments: Amortization of acquired intangible assets (1) 48.2 44.9 Impairment of intangible
Slide 40: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) Reconciliation of Non-GAAP Income Statement Presented on Page 29 Three Months Ended March 29, 2025 March 30, 2024 Operating Expenses: GAAP operating expenses 384.3 331.9 Adjustments: Amortization of acquired intangible assets (1) (3.8) (5.7) Impairment
Slide 41: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) Reconciliation of Non-GAAP Income Statement Presented on Page 29 Three Months Ended March 29, 2025 March 30, 2024 Pre-Tax Income (Loss): GAAP pre-tax earnings (loss) (28.5) 211.5 Adjustments to pre-tax earnings (loss) as detailed above 308.6 99.5 Debt e
Slide 42: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) Reconciliation of Non-GAAP Income Statement Presented on Page 29 Three Months Ended March 29, 2025 March 30, 2024 Net Income (Loss) Percentage: GAAP net income (loss) percentage (1.7%) 16.7% Impact of adjustments above 24.9% 7.3% Non-GAAP net income per
Slide 43: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) Explanatory Notes to Reconciling Items Presented on Pages 39-42 (1) To reflect non-cash expenses attributable to the amortization of acquired intangible assets. (2) To reflect the fair value write-up of inventory sold during the period related to the En
Slide 44: Reconciliation of GAAP to Non-GAAP (unaudited)
Reconciliation of GAAP to Non-GAAP (unaudited) Explanatory Notes to Reconciling Items Presented on Pages 39-42 (10) Non-GAAP earnings per share was calculated based on 226,991 and 229,549 weighted average diluted shares outstanding for the three and six months ended March 29, 2025, respectively, and
Slide 45: Reconciliation of Non-GAAP EPS Guidance
Reconciliation of GAAP to Non-GAAP (unaudited) Reconciliation of Non-GAAP EPS Guidance Presented on Page 30 Guidance Range Quarter Ending Year Ending June 28, 2025 September 27, 2025 Low High Low High GAAP Net Income Per Share 0.85 0.88 2.47 2.57 Amortization of acquired intangible assets 0.20 0.20
Slide 46: Reconciliation of Net Debt and Leverage Ratio
Reconciliation of Net Debt and Leverage Ratio Reconciliation of Net Debt and Leverage Ratio Presented on Page 26 As of March 29, 2025 Net Leverage Ratio: Total principal debt 2,528.8 Total cash and cash equivalents (1,429.5) Net principal debt 1,099.3 EBITDA for the last four quarters 1,313.9 Net Le
Slide 47: Capitalization as of Q2'25
Capitalization as of Q2’25 Note: Dollars in millions. 47
Slide 48: COVID Assay and Related Revenue
COVID Assay and Related Revenue COVID Assay and Related Revenue* $823 $800 $760 $700 $664 $661 $600 $596 $514 $500 $400 $365 $352 $300 $215 $200 $187 $163 $100 $98 $55 $45 $52 $53 $38 $40 $44 $37 $0 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 C